ArQule: ARQ 531-101 Ph1 ARQ 531 R/R Hematologic Malignancies

What is the Purpose of this Study?

If you choose to join this study, you will:
- Give samples of your blood
- Have assessments of your vital signs
- Give urine samples
- Get the study drug, ARQ 531, taken by mouth for one week
What is the Condition Being Studied?
Relapsed or Refractory Hematologic Malignancies

Who Can Participate in this Study?

Adults who:

- Have good organ function

- Have a platelet count greater than 50,000/microliters

- Have a creatinine clearance of greater than 60 mL/min

- Have hemoglobin (Hgb) greater than 8.0 g/dL and stable for greater than 1 week

Age Group
Participating Institutions

What is Involved?

We are doing this study to find out what is the best dose of the study drug (ARQ 531) to use in patients with hematologic malignancies.

Study Details

Full Title
A Phase 1 Dose Escalation Study to Investigate the Safety, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of ARQ 531 in Selected Subjects with Relapsed or Refractory Hematologic Malignancies
Principal Investigator

Protocol Number

View on